All In Biotech

Drug Trial Radar · NCT04720976

JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors

A Phase 1/2a, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 Based Combination Therapies in Adult Patients With Advanced Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

58

Actual

Start

Mar 23, 2021

Primary completion

Dec 19, 2023

Study completion Dec 19, 2023

Sponsor

Lead sponsor
Allist Pharmaceuticals, Inc.Industry
Sponsor type
Industry
Collaborators
AbbVie
First posted
Jan 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of JAB-3312 administered in investigational regimens in adult participants with advanced solid tumors.

Conditions

  • Solid Tumor
  • NSCLC

Interventions

  • JAB-3312Drug

    JAB-3312 will be administered orally, variable dose.

  • BinimetinibDrug

    Binimetinib will be administered orally.

  • PembrolizumabDrug

    Pembrolizumab will be administered as an intravenous infusion.

  • SotorasibDrug

    Sotorasib will be administered orally.

  • OsimertinibDrug

    Osimertinib will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose limiting toxicitiesTime frame: 24 months
  2. Objective response rate (ORR)Time frame: 24 months
  3. Duration of response (DOR)Time frame: 24 months
  4. Duration of response (DCR)Time frame: 24 months
  5. Progression-free survival (PFS)Time frame: 24 months
  6. Overall survival (OS)Time frame: 24 months
  7. Number of participants with adverse eventsTime frame: 24 months

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    New Haven, Connecticut

  • Research Site

    Jacksonville, Florida

  • Research Site

    Orange City, Florida

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    Detroit, Michigan

  • Research Site

    Rochester, Minnesota

  • Research Site

    St Louis, Missouri

  • Research Site

    New York, New York

  • Research Site

    Oklahoma City, Oklahoma

  • Research Site

    Houston, Texas

  • Research Site

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.